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Objective To assess the ability of 59 clinical microbiology laboratories distributed
throughout Italy to correctly identify and detect reduced susceptibility to glycopeptides
in staphylococci and VanA-, VanB- or VanC-mediated glycopeptide resistance in en-
terococci.
Methods Eight test strains comprising three staphylococci (S. aureusATCC29212 and two
vancomycin-intermediate S. haemolyticus [11105301, 10030683Y]) and ﬁve enterococci (E.
faecalisATCC 29212, E. faecalisATCC 51299 VanB, E. faeciumAIB40 VanA, E. faecalis V583
VanB and E. gallinarumAIB39 VanC1) were distributed to 59 Italian clinical microbiology
laboratories. Each isolatewas blind-coded, and laboratorieswere instructed to identify the
strains and test isolates for susceptibility to teicoplanin and vancomycin using their
standard methods. Results were assessed against consensus test results obtained by a
reference laboratory. In addition, to complement data interpretation, laboratories were
asked to provide retrospective routine test results from their respective hospitals.
Results All 59 laboratories participating in the study completed the susceptibility testing
and provided data for analysis. A total of 53 laboratories provided retrospective routine
data. Overall, laboratories were able to identify isolates to the genus level successfully.
E. gallinarum and S. haemolyticus posed problems for species identiﬁcation, with only 40.6
and 71.2%, respectively, of results reported correctly; most incorrect results were
reported as ‘other species’. For enterococcal test strains, VanA phenotypes were detected
correctly by 96.6% of laboratories; VanB by 30.5% (E. faecalis ATCC 51299) and 88.1% (E.
faecalis V583); and VanC1 by 67.8%. For staphylococcal test strains, 28.8% (S. haemolyticus
11105301) and 23.7% (S. haemolyticus 10030683Y) of the laboratories were able to
detect reduced susceptibility to vancomycin. Errors in detecting vancomycin resistance
in VanB and VanC1 enterococci were made with all methods, most noticeably by disk
diffusion users. For staphylococci, most errors in reporting vancomycin-intermediate
resistance occurred with disk diffusion and VITEK (software version 5.04) users. Overall,
considerably fewer errors occurredwith the detection of teicoplanin resistance, especially
for staphylococci. For 1999, routine results show that 41/1749 (2.4%) of E. faecium, 220/
11 180 (2.0%) of E. faecalis, 29/24 927 (0.12%) of S. aureus and 54/22 102 (0.24%) of
coagulase-negative staphylococci were reported as resistant to vancomycin.
Conclusion Italian laboratories are able to identify staphylococci and enterococci ade-
quately, although all methodologies used have problems in identifying E. gallinarum and
coagulase-negative staphylococci to the species level. While VanA phenotypes were efﬁ-
ciently detected, problems were experienced in detecting VanB and VanC phenotypes.
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The majority of laboratories were unable to detect reduced vancomycin susceptibility
in staphylococci adequately, especially with disk diffusion and older VITEK systems.
Teicoplanin appeared useful as a marker for detecting vancomycin resistance, partic-
ularly with disk diffusion. Should enterococcal VanB or staphylococcal glycopeptide-
intermediate phenotypes become prevalent in Italy, it is likely that they would be
under-detected. New systems under development, such as VITEK2, should improve this
situation.
Keywords Glycopeptides, resistance, proﬁciency-testing
Clin Microbiol Infect 2002; 8: 101–111
INTRODUCTION
The glycopeptides vancomycin and,more recently,
teicoplanin have become the standard treatment
for infections caused by Gram-positive organisms
such as oxacillin-resistant Staphylococcus aureus
(ORSA, MRSA), enterococci and invasive penicil-
lin-resistant pneumococci.
Vancomycin-resistant enterococci (VRE) have
emerged as a serious clinical problem in the
USA [1,2], where approximately 20% of the
isolates of this genus are now resistant [3,4]. In
contrast, in Europe the incidence remains gener-
ally low, with the most recent international sur-
veillance study recording an aggregate incidence
of vancomcyin resistance of 3.8% in Enterococcus
faecium and 0.06% in E. faecalis [5]. A previous
retrospective study of routine clinical data from
Italian laboratories noted a vancomycin-resistance
rate of 10% among E. faecium, with an overall rate
of VRE of 1.6% [6]. Resistance in this genus is
mediated by one of at least seven functionally
homologous gene loci, including vanA, vanB,
vanC1, vanC2/C3, vanD, vanE and vanG [7–12],
although vanA and vanB appear most clinically
relevant and widespread to date [1,2]. The loci
vanA, vanB, vanD and vanE encode acquired
mechanisms; vanC1, vanC2/vanC3 and vanG loci
specify chromosomally encoded alternative ligase
enzymes with a low binding afﬁnity for vancomy-
cin and/or teicoplanin. Although reports of coa-
gulase-negative staphylococci (CNS) intermediate
or resistant to teicoplanin are not uncommon
[13,14], similar reports remain rare as far as van-
comycin is concerned [15,16]. However, there have
been recent reports of vancomycin- or teicoplanin-
nonsusceptible S. aureus [17–20].
Clinical microbiological laboratories are re-
quired to identify and test infecting bacterial
pathogens accurately for susceptibility to antimi-
crobial agents, providing guidance to physicians
on therapeutic options. This is also an important
ﬁrst step in providing surveillance data for use
in local and national aggregate databases. For
Enterococcus, VanA-mediated high-level glycopep-
tide resistance can be detected easily; however,
VanB- and VanC-mediated low-level resistance,
often inducible, is difﬁcult to detect, especially
with automated test equipment [21]. Similarly,
detecting reduced susceptibility to vancomycin
and teicoplanin in staphylococcal species is a
challenge to clinical laboratories, and a previous
study has shown that automated equipment,
especially rapid, short-incubation-time systems
and disk diffusion methodologies, are unreliable
[22].
This report describes a proﬁciency test under-
taken to assess the ability of Italian clinical labora-
tories to detect reduced glycopeptide susceptibility
in clinical isolates of enterococcal and staphylo-
coccal species using daily routine methodologies.
MATERIALS AND METHODS
Bacterial strains
Eight organisms were selected from the Focus
Technology strain repository, comprising ﬁve
Enterococcus spp. and three Staphylococcus spp.
(Table 1). The ﬁve enterococci included three clin-
ical isolates (one each of E. faecium, E. faecalis and
E. gallinarum) and two American Type Culture
Collection (ATCC) control strains of E. faecalis.
Together these included representative organisms
expressing vanA, vanB and vanC1 gene loci. The
three staphylococci comprised two clinical isolates
of S. haemolyticus and one ATCC control strain of
S. aureus. Both S. haemolyticus isolates demonstra-
ted homogeneous vancomycin-intermediate phe-
notypes. Isolates were rendered anonymous by
blind-coding the designation number of each strain
used throughout the study. Prior to the study, the
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identity of each isolate was conﬁrmed to species
level usingmethods outlined in theASMManual of
Clinical Microbiology [23]. Each test organism was
tested for its susceptibility to teicoplanin and van-
comycin on three separate occasions using disk
diffusion and microbroth dilution as deﬁned by
NCCLS [24]. The presence of vanA, vanB and
vanC1 was conﬁrmed using previously described
oligonucleotide primer sets and polymerase chain
reaction protocols [25]. These data provided refer-
ence results to which all participating laboratory
test results were compared.
Participating laboratories
A total of 59 Italian hospital microbiological
laboratories were invited to participate in the
study. All participant laboratories were members
of the Associazione Microbiologi Clinici Italiani
(AMCLI) and were distributed throughout main-
land Italy, Sicily and Sardinia.
Proficiency test procedure, organism
identification and susceptibility testing
Fresh overnight cultures of each of the eight organ-
ismsmade anonymous were subcultured on nutri-
ent agar screw-top transport slopes (bioMe´rieux
S.p.A, Rome, Italy) and, together with a data report
sheet and concise study protocol, were distributed
by courier to each of the participating hospitals on
the same day, during the summer of 1999.
Laboratories were instructed to process the test
organisms on the day of receipt, using the same
routine methodologies and procedures they
would use for any blood isolate. For each test
isolate, the data report sheet requested the genus
and species, susceptibility test method used and
both quantitative and qualitative susceptibility test
results for teicoplanin and vancomycin. On a sepa-
rate questionnaire, each laboratory was polled for
information concerning hospital demographics,
routine microbiological operating procedures,
and staphylococcal and enterococcal incidence
and susceptibility data for 1999. All laboratories
undertook susceptibility testing and interpretation
of results using NCCLS standards [24], which is
used as the standard throughout Italy.
Identification and susceptibility test
systems used
The 59 hospital laboratories included in this study
reported using a range of technologies for routine
isolate identiﬁcation and susceptibility testing. For
identiﬁcation of streptococci or staphylococci,
laboratories used API strips (bioMe´rieux S.p.A,
Rome, Italy) (14–16 laboratories), ATB system (bio-
Me´rieux S.p.A) (four laboratories), MICROSCAN
(DadeBehring, Milan, Italy) (eight laboratories),
SCEPTOR (Becton-Dickenson, Milan, Italy) (9–10
laboratories), VITEK (bioMe´rieux) (17–20 labora-
tories) and noncommercial manual systems (two
laboratories). For susceptibility testing, laboratories
useddiskdiffusion (15–19 laboratories),MICROSCAN
(eight laboratories), SCEPTOR (9–10 laboratories),
VITEK (17–22 laboratories), API (two laboratories)
and SENSITITRE (Trek Diagnostic Systems, Milan,
Italy) (one laboratory). E test (ABiodisk, Solna,
Sweden) data were reported sporadically to
Table 1 MIC and disk diffusion zone sizes and susceptibility phenotypes for eight test strains as reported by reference
laboratory
MIC (mg/L), interpretation, and [zone size
(mm) interpretation]a
Test strain Glycopeptide-R genotype Teicoplanin Vancomycin
1. E. faecalis (ATCC 29212) None 0.5, S; [20, S] 2, S; [19, S]
2. E. faecalis (ATCC 51299) VanB 0.5, S; [20, S] 64, R; [0, R]
3. E. faecium (AIB40) VanA >32, R; [11, I] >128, R; [0, R]
4. E. faecalis (V583) VanB 1, S; [19, S] 64, R; [0, R]
5. E. gallinarum (AIB39) VanC1 2, S; [19, S] 8, I; [18, S]
6. S. aureus (ATCC 29213) None 1, S; [19, S] 0.5, S; [20, S]
7. S. hemolyticus (11105301) Unknown 64, R; [11, I] 8, I; [19, S]
8. S. hemolyticus (10030683Y) Unknown 128, R; [0, R] 8, I; [18, S]
aAccording to NCCLS criteria [24]; S, susceptible; I, intermediate; R, resistant.
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conﬁrm a number of susceptibility test results (0–3
laboratories per test strain). Non-reporting of the
test method varied per strain, but occurred at <2
sites per strain (3.4%).
Data reporting and analysis
Quantitative susceptibility test data were inter-
preted and reported using NCCLS-deﬁned break-
points [24] by all laboratories in the study. For
purposes of analysis, the qualitative susceptibility
results were considered, since these represent
the susceptibility data ﬁnally reported from
the laboratory to clinicians. The qualitative re-
sult obtained by the reference laboratory using
broth microdilution was taken as the reference
data-point to which all other data-points were
compared. It should be noted that complete con-
cordance between disk diffusion and broth micro-
dilution results was obtained in all cases except
with strains 3 and 7 for teicoplanin, and strains 5, 7
and 8 for vancomycin. Errors for reported suscept-
ibility tests were categorized using an established
system [26]. Errors were deﬁned as follows: minor
(resistant or susceptible reported as intermediate;
intermediate reported as either susceptible or
resistant), major (susceptible reported as resistant),
and very major (resistant reported as susceptible).
RESULTS
Study participation and hospital-specific
information
Of the 59 hospital laboratories invited to partic-
ipate in the study, all (100%) completed the pro-
ﬁciency test and returned a completed data
report sheet; 53 hospitals (89.8%) returned retro-
spective information concerning microbiological
and prevalence information for the year 1999,
although not all questions were always answer-
ed. All data entered into report sheets were eva-
luable and included in the ﬁnal data analysis
(Table 2).
Hospital laboratories participating in this study
comprised tertiary care, non-university hospitals
serving local communities, with an average bed
size of 606. The majority of the 53 laboratories that
responded to the survey (>90%) routinely tested
enterococcal blood and non-blood isolates against
vancomycin, and enterococcal blood isolates
against teicoplanin (Table 2). For staphylococci,
>90% of blood and non-blood isolates were tested
against vancomycin, as were non-blood isolates
against in teicoplanin. Few laboratories used an
agar method to screen for vancomycin resistance
against in either genus. Of the 19 laboratories using
disk diffusion as a susceptibility test method, only
nine of 16 respondents (56.3%) routinely per-
formed follow-up testing on vancomycin-non-sus-
ceptible enterococci detected by disk diffusion
with a minimum inhibitory concentration (MIC)
method. From the 46 laboratories returning retro-
spective susceptibility information, 0.12% of S.
aureus, 0.24% of coagulase-negative staphylococci,
2.6% of E. faecium and 2.4% of E. faecalis isolates
were reported as vancomycin-nonsusceptible
(Table 2).
Ability of laboratories to identify study
isolates correctly
Hospitals reported the use of a variety of bacterial
identiﬁcation technologies to identify test organ-
isms. VITEK was the most commonly used system
of identiﬁcation in up to 19 of the participating
laboratories, depending on the test strain in ques-
tion. API systems (API-STREP or API-STAPH) were
used in 15 laboratories, MICROSCAN WALKAWAY in
nine, SCEPTOR in eight, ATB in three and manual
methods (no kits) in two. The success in identify-
ing each of the study strains correctly to the genus
or species level is reported in Table 3. At least 57 of
the 59 laboratories correctly identiﬁed each of the
enterococcal test organisms to the genus level. All
laboratories correctly identiﬁed all staphylococcal
species to the genus level. No strain was correctly
identiﬁed to the species level by all participating
laboratories. For E. faecalis and E. faecium, more
than 90% of laboratories correctly reported the
organism to species level. Fewer than half the
laboratories reported the species correctly for
strain 5, E. gallinarum, although ﬁve laboratories
did not speciate the strain, reporting only ‘Enter-
ococcus spp.’ Nearly all laboratories (58 of 59)
were able to correctly identify strain number 6
as S. aureus. For the two strains of S. haemolyticus,
strains 7 and 8, only 50 and 42 laboratories, respec-
tively, correctly identiﬁed the species, while ﬁve
laboratories reported only ‘Staphylococcus spp.’
for both strains. Incorrect identiﬁcations were re-
ported with each of the identiﬁcation systems
used in participating laboratories, as shown in
Table 3.
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Susceptibility testing of enterococcal species
Error rates for susceptibility data reported for
enterococci, test strains 1–5, are shown in Table 4.
Strain 1, the susceptible control strain, was
reported as either intermediate or resistant to
vancomycin by 23.7% of laboratories. Importantly,
few laboratories had difﬁculty in detecting vanco-
mycin resistance in strain 3, expressing a VanA
phenotype, although the two incorrect results
were very major errors, with the organism
reported as susceptible. Errors in susceptibility
testing for strains 2 and 4, both expressing a VanB
phenotype, were reported in 69.5 and 11.9% of
laboratories, respectively; 40.7 and 10.2% of these
results were major errors. Strain 5, expressing a
VanC1 phenotype, was erroneously reported as
susceptible or resistant to vancomycin by 32.2% of
laboratories, eight of which reported it as suscep-
tible. It should be noted that the reference labora-
tory was not able to detect intermediate resistance
using the NCCLS-deﬁned disk diffusion metho-
dology. For teicoplanin, laboratories performed
much better overall, with fewer errors, although
it should be noted that, unlike for vancomycin,
isolates remained mostly susceptible to this com-
pound. Interestingly, strain 3 (VanA phenotype),
which was also resistant to teicoplanin by MIC
methodologies, was reported as susceptible by 19
(32.2%) laboratories.
Table 2 Routine clinical practices and glycopeptide-resistance prevalence data in 1999 for the 59 participating laboratories
Genera-specific information
requested
No. (%) of participating
laboratories
responding
No. (%) of
responding laboratories
with routine practicea
No. (%) of
isolates
Enterococcus spp.
Routine susceptibility testing of
blood isolates
Vancomycin 53 (89.8) 51 (96.2)
Teicoplanin 53 (89.8) 50 (94.3)
Routine susceptibility testing
of non-blood isolates
Vancomycin 53 (89.8) 48 (90.6)
Teicoplanin 53 (89.8) 42 (79.2)
Routine use of a vancomycin agar
screen method
53 (93.2) 11 (20.8)
Routine follow-up using MIC method
for Van-Ib and Van-Rc enterococci
detected using disk diffusion
16 (from 19 disk
diffusion users)
9 (56.3)
Total number of Van-R E. faecium
reported during 1999
46 (86.7) 41/1749d (2.4)
Total number of Van-R E. faecalis
reported during 1999
46 (86.7) 220/11,180d (2.0)
Staphylococcus spp.
Routine susceptibility testing
of blood isolates
Vancomycin 53 (89.8) 49 (92.5)
Teicoplanin 53 (89.8) 46 (75.5)
Routine susceptibility testing of
non-blood isolates
Vancomycin 53 (89.8) 52 (98.1)
Teicoplanin 53 (89.8) 49 (92.5)
Routine use of an agar screen method 53 (89.8) 21 (39.6)
Total Van-I or Van-R S. aureus
reported during 1999
48 (81.35) 29/24927 (0.12)
Total Van-I or Van-R CNSe reported
during 1999
45 (77.9) 54/22102 (0.24)
aMedian hospital-bed size, 606 beds (n¼ 53).
bVan-I ¼ vancomycin-intermediate.
cVan-R ¼ vancomycin-resistant.
dRetrospective data combining all test methodologies.
eCNS ¼ coagulase-negative staphylococci.
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Susceptibility testing of staphylococcal species
Error rates for susceptibility data reported for
staphylococci, test strains 6–8, are shown in
Table 5. Two laboratories reported the susceptible
control strain as intermediate to vancomycin; 71.2
and 76.3% of results reported for the vancomycin-
intermediate strains 7 and 8, respectively, were
minor errors. Of these 40/59 laboratories (67.8%)
and 42/59 laboratories (72.9%) reported strains 7
and 8, respectively, as susceptible. For test strains 7
and 8, which were teicoplanin-resistant (according
to MIC broth microdilution methodologies),
laboratories were able to detect reduced suscept-
ibility more easily, although 32.2 and 22.0% of
laboratories, respectively, reported strains 7 and
8 as intermediate (minor errors), and 6.8 and
20.3%, respectively, reported them as susceptible
(very major errors). Figure 1 compares the vanco-
mycin susceptibility results reported by the 59 test
laboratories with the reference laboratory broth
microdilution results for each test strain according
to the test methodology used. Data derived from
E test, ATB and SENSITITRE systems were exclu-
ded due to low numbers of results. Figure 2 illus-
trates the superior ability of teicoplanin to detect
reduced glycopeptide susceptibility in Staphylococ-
cus species. For susceptible S. aureus strain 6, mean
zone sizes reported for vancomycin and teicoplanin
were similar at 17.7mm and 16.9mm (Figure 2a).
In contrast, for vancomycin-intermediate strain 7
(Figure 2b), a clear differentiation is apparent.
The mean zone size for vancomycin was reported
as 17.5mm, essentially identical to that reported
for susceptible strain 6 and above the 14-mm
resistance breakpoint, while for teicoplanin, the
Table 4 Error rates for quantitative susceptibility test results reported for Enterococcal species
Susceptibility
(mg/L; mm)
No. of errors (% of laboratories)
Test strain Total errors Very major Major Minor
Vancomycin
1. E. faecalis (Van-Sa) 2 [S]; 19 [S] 14 (23.7) 0 (0) 7 (11.9) 7 (11.9)
2. E faecalis (VanB) 64 [R]; 0 [R] 41 (69.5) 24 (40.7) 0 (0) 17 (28.8)
3. E faecium (VanA) >128 [R]; 0 [R] 2 (3.4) 2 (3.4) 0 (0) 0 (0)
4. E. faecalis (VanB) 64 [R]; 0 [R] 7 (11.9) 6 (10.2) 0 (0) 1 (1.7)
5. E. gallinarum (VanC1) 8 [I]; 18 [S] 19 (32.2) 0 (0) 0 (0) 19 (32.2)
Teicoplanin
1. E. faecalis (Van-S) 0.5 [S]; 20 [S] 2 (3.4) 0 (0) 1 (1.7) 1 (1.7)
2. E faecalis (VanB) 0.5 [S]; 20 [S] 3 (5.1) 0 (0) 0 (0) 3 (5.1)
3. E faecium (VanA) >32 [R]; 11 [I] 19 (32.2) 7 (11.9) 6 (10.2) 6 (10.2)
4. E. faecalis (VanB) 1 [S]; 19 [S] 4 (6.8) 0 (0) 2 (3.4) 2 (3.4)
5. E. gallinarum (VanC1) 2 [S]; 19 [S] 1 (1.7) 0 (0) 0 (0) 1 (1.7)
aS, susceptible; I, intermediate; R, resistant.
Table 5 Error rates for quantitative susceptibility test results reported for staphylococcal species
Susceptibility
(mg/L; mm)
No. of errors (% of laboratories)
Test strain Total errors Very major Major Minor
Vancomycin
6. S. aureus (Van-Sa) 0.5 [S]; 20 [S] 2 (3.4) 0 (0) 0 (0) 2 (3.4)
7. S. hemolyticus (Van-I) 8 [I]; 19 [S] 42 (71.2) 0 (0) 0 (0) 42 (71.2)
8. S. hemolyticus (Van-I) 8 [I]; 18 [S] 45 (76.3) 0 (0) 0 (0) 45 (76.3)
Teicoplanin
6. S. aureus (Van-S) 1 [S]; 19 [S] 1 (1.7) 0 (0) 0 (0) 1 (1.7)
7. S. hemolyticus (Van-I) 64 [R]; 11 [I] 23 (39) 0 (0) 4 (6.8) 19 (32.2)
8. S. hemolyticus (Van-I) 128 [R]; 0 [R] 25 (42.4) 0 (0) 12 (20.3) 13 (22.0)
aS, susceptible; I, intermediate; R, resistant.
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mean reported zone size decreased to 11.7mm,
comfortably below the current 13-mm resistance
breakpoint.
DISCUSSION
This study speciﬁcally addressed the issue of
whether laboratories using routine methodologies
were able to test staphylococci and enterococci for
their susceptibility to glycopeptides correctly. Mis-
identiﬁcation of the infecting organism, and over-
or under-reporting of resistance can have serious
ramiﬁcations for the patient, resulting in the
prescription of a less than optimal antimicrobial
agent. In addition, there is the wider utility of the
data to consider. Susceptibility test results pro-
duced in clinical laboratories are also invaluable
as a data source for use in surveillance. In this
respect, incorrect identiﬁcation and susceptibility
test results can have ramiﬁcations that go beyond
the individual patient. Are laboratories able to
detect glycopeptide resistance in enterococci and
staphylococci?
Most of the Italian laboratories included in this
study were able to identify isolates to the genus
level adequately. Enterococcal test strains were
misidentiﬁed most often as another enterococcus
species. This occurred with all identiﬁcation sys-
tems used (Table 3). All laboratories were able to
identify staphylococci to the genus level. While
S. aureus posed no problems, both strains of S.
haemolyticus were often misidentiﬁed, most often
asanotherstaphylococcalspecies. It shouldbenoted
that correct speciation was strain-speciﬁc. While
50 laboratories correctly identiﬁed strain 7 as
Figure 1 Percentage of correct (no
errors) reported susceptibility re-
sults, by method used. The number
of sites using each susceptibility
test method is given in parentheses
and varied per test strain.
Figure 2 (a) Comparative vancomycin and teicoplanin
zone-size distributions reported from all sites for vanco-
mycin-susceptible strain 6 (S. aureus ATCC 29212). Mean
vancomycin zone size, 17.6mm; mean teicoplanin zone
size, 16.9mm. (b) Comparative vancomycin and teicopla-
nin zone-size distributions reported from all sites for
vancomycin-intermediate strain 7 (S. hemolyticus). Current
NCCLS-defined [24] zone-size resistance cut-off points for
vancomycin (V) and teicoplanin (T) are marked. Mean
vancomycin zone size, 17.5mm; mean teicoplanin zone
size, 11.7mm.
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S. haemolyticus, only 42 laboratories correctly iden-
tiﬁed strain 8. Although few of the misidentiﬁca-
tions would have had any impact on patient
therapy, incorrect data would have been for-
warded to surveillance databases. It is recom-
mended that organisms displaying rare or
unusual susceptibility phenotypes, such as van-
comycin-resistant enterococci or staphylococci,
should be re-identiﬁed, using another method.
Enterococci expressing the VanA phenotype,
most often encoded by conjugative plasmids, pose
the biggest threat to health care. These isolates
(generally E. faecium) are highly resistant to both
vancomycin and teicoplanin and pose problems
for infection control because of the need to limit
clonal expansion as well as prevent horizontal
plasmid transmission [1,2]. Laboratories were able
to detect high-level vancomycin resistance
(>128mg/L) in all but two cases, both reported
as susceptible (very major errors). The accurate
detection of VanB (64mg/L) proved more difﬁcult
and varied signiﬁcantly depending on the method
used and also between the two test strains (strains
2 and 4). While only 15 laboratories (30.4%) cor-
rectly reported strain 2 as resistant to vancomycin,
52 laboratories (88.1%) were able to test the sus-
ceptibility of strain 3 correctly. Despite vancomy-
cin yielding identical MIC valves and zone sizes
for both isolates, according to the reference labora-
tory, much disparity between the two strains was
reported, clearly illustrating strain-speciﬁc varia-
bility between resistant types. A previous study
[27] also reported differences in the proﬁciency of
laboratories in detecting VanB phenotypes for two
different strains (77.3 and 59.1%, respectively),
although the MICs of vancomycin against the test
strains were not identical, one expressing med-
ium-level vancomycin resistance and the other
expressing low-level resistance. For strain 3,
approximately half of all errors were minor errors
and half were very major errors, all reported from
those using VITEK, SCEPTOR and disk diffusion tech-
niques. In contrast, for strain 4, users of the VITEK
and SCEPTOR methods correctly identiﬁed vanco-
mycin resistance, while very major errors were re-
ported by users of disk diffusion and MICROSCAN
techniques.Strain5,E.gallinarumexpressingVanC1,
also posed considerable problems, with 19 labora-
tories reporting minor errors. The majority of these
three laboratories were using disk diffusion. VITEK
users tended to over-report resistance, with three
sites reporting a resistant phenotype.
To date, at least three previous studies have
attempted to measure the proﬁciency with which
laboratories can detect vancomycin resistance in
Enterococcus species. Richardson et al. [28] reported
that 94% of 364 participating Canadian labora-
tories were able to detect low-level vancomycin
resistance in a strain of E. faecium vanB. A similar
study undertaken in Spain [27] reported that 90.9%
of 22 participating laboratories were able to de-
tect correctly VanA-mediated resistance, whereas
VanB- and VanC-mediated resistance was cor-
rectly detected in only 59.1 and 50% of labora-
tories, respectively. A separate Spanish study [29]
also reported a 97.2% success rate in the correct
detection of E. faecalis displaying a VanA pheno-
type. The Italian laboratories in the current study
showed a similar level of proﬁciency in detecting
VanA phenotypes, correctly reported by 96.6% of
laboratories. Interestingly, disk diffusion was lar-
gely responsible for incorrect results in these pre-
vious studies, while in this study, all those using
disk diffusion correctly detected the VanA pheno-
type. Similarly to previous proﬁciency studies, the
lower the level of vancomycin resistance, the more
difﬁcult it was to detect.
Both S. hemolyticus isolates posed signiﬁcant
problems for laboratories in detecting intermedi-
ate resistance to vancomycin, with 71.2 and 76.3%
of laboratories failing to report reduced suscept-
ibility. A similar result was recently reported by
Tenover et al. for laboratories around the world
[30]. This study found that by far the majority of
incorrect results were from disk diffusion and
VITEK users reporting isolates as susceptible. Other
methods fared better, with the SCEPTOR system
performingmost successfully. VITEK systems using
software version 5.04 are known to have difﬁcul-
ties detecting vancomycin resistance in staphylo-
cocci, and the company has since released system
updates to improve detection of glycopeptide
resistance. At the time of this study, the majority
of those using VITEK were still using software ver-
sion 5.04. Isolates tested using VITEK and reported
as having a vancomycin MIC of 4mg/L could in
fact be less susceptible to vancomycin and should
be re-tested with an alternative MIC method. Disk
diffusion is not sufﬁciently sensitive, and is there-
fore an inadequate method for testing organisms
to vancomycin susceptibility. A far greater propor-
tion of sites correctly detected isolates intermedi-
ate or resistant to teicoplanin. As is shown in
Figure 2 for those sites reliant on disk diffusion
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as a primary test method, teicoplanin may offer a
useful indicator for reduced susceptibility to van-
comycin. Teicoplanin is generally more active than
vancomycin enterococci (although VanA pheno-
types are still mostly resistant to this compound),
yet considerably more errors were reported for
teicoplanin than for vancomycin.
Current NCCLS guidelines state that all staphy-
lococci with a vancomycin zone size of 14mm or
less and any Enterococcus spp. with an intermedi-
ate zone size of 11–13mm should be tested by a
MIC method. At most, three sites reported MICs
for vancomycin-resistant or vancomycin-inter-
mediate test strains; however, it is likely that the
study protocol did not allow an accurate assess-
ment of this practice. Nonetheless, only 56.3% of
disk diffusion users (Table 2) reported the routine
use of a MIC method to conﬁrm glycopeptide
resistance detected by disk diffusion methods.
Finally, what can we conclude from this study
about the levels of vancomycin resistance in Italy?
Clearly, some degree of species misidentiﬁcation
occurs, but this is unlikely to affect the assessment
of the overall prevalence of glycopeptide resis-
tance. Previous concerns have been raised about
the ability of laboratories to detect vancomycin
resistance, especially low-level resistance, which
may result in an underestimation of resistance,
especially among enterococci, in Europe [27].
The 53 participating laboratories that provided
routine retrospective data reported 2.4% of all E.
faecium and 2.0% of all E. faecalis as vancomycin-
resistant in 1999. It is likely that VanA phenotypes
are accurately detected irrespective of the method
used. In contrast, for strain 2, harbouring vanB,
37.3% of the results were very major errors (resis-
tant reported as susceptible). Depending on the
true prevalence of vanB in the population, resis-
tance or non-susceptibility could be under-
reported, irrespective of the test method. This
under-reporting may be offset to a small degree
by false resistance reporting. For Staphylococcus
spp., 0.12% of S. aureus and 0.24% of CNS were
reported as non-susceptible to vancomycin. Since
no test method was able to distinguish vancomy-
cin-intermediate isolates well, reporting them
as susceptible, the true number of vancomycin-
nonsusceptible isolates could be higher. Clearly, if
the incidence of vancomycin non-susceptibility
increases among staphylococci, the majority of
laboratories will not be able to detect this pheno-
type efﬁciently based on current methods and
performance. However, since most laboratories
also regularly test teicoplanin, unusual isolates
with respect to glycopeptide susceptibility are
likely to be detected. New automated test systems,
such as VITEK2 (bioMe´rieux), have improved abil-
ity to detect reduced vancomycin susceptibility,
especially in enterococci [31,32]. In addition, pro-
ﬁciency studies are an important indicator of the
ability of laboratories to detect resistance, espe-
cially emerging resistance, and can serve as an
educational tool to help improve our capabilities in
the prevention and control of resistance.
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